DAVID R. SNYDMAN, M.D.; JOHN A. BRYAN, M.D.; RICHARD E. DIXON, M.D.
Nosocomial viral hepatitis, type B, is assuming increasing importance in the United States. The keystone to an effective hepatitis control program is surveillance of patients and personnel, especially in high-risk areas, namely dialysis units, hematology-oncology units, and laboratories. Measures to control infection are outlined for specific areas of the hospital. Data currently available suggest that employees who have persisting hepatitis B surface antigen (HBsAg) need not be removed from their positions unless they have been proved to disseminate infection. Future investigations should include methods to study: [a] the mechanisms of non percutaneous spread of hepatitis B virus, [b] the role of the individual with persisting HBsAg in the dissemination of hepatitis B virus, [c] the efficacy of hepatitis B immune globulin in high-risk areas, and [d] the effectiveness of various chemical and physical procedures in use for inactivation of hepatitis B virus using animal model systems.
SNYDMAN DR, BRYAN JA, DIXON RE. Prevention of Nosocomial Viral Hepatitis, Type B (Hepatitis B). Ann Intern Med. ;83:838–845. doi: 10.7326/0003-4819-83-6-838
Download citation file:
Published: Ann Intern Med. 1975;83(6):838-845.
Gastroenterology/Hepatology, Infectious Disease, Liver Disease, Viral Hepatitis.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use